Mediwound announces pricing of public offering of ordinary shares

Yavne, israel, march 03, 2022 (globe newswire) -- mediwound ltd. (nasdaq: mdwd) (“mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced the pricing of an underwritten public offering of 5,208,333 ordinary shares at a public offering price of $1.92 per share. the gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $10 million. all of the shares in the offering are to be sold by mediwound. the offering is expected to close on or about march 7, 2022, subject to the satisfaction of customary closing conditions. mediwound also granted the underwriters a 30-day option to purchase up to an additional 781,249 ordinary shares at the public offering price, less underwriting discounts and commissions
MDWD Ratings Summary
MDWD Quant Ranking